Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ARG1 | P05089 | 2/20 | 0.55 |
| ▸ | ARG2 | P78540 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12583604 | 1.00 | HIF1A (0.60) | HIF1ASMN1; SMN2ARG1ARG2SLC6A2 | |
| SCHEMBL11265744 | 1.00 | HIF1A (0.60) | HIF1ASMN1; SMN2ARG1ARG2SLC6A2 | |
| SCHEMBL8351006 | 0.88 | SMN1; SMN2 (0.69) | HIF1ASMN1; SMN2ARG1ARG2SLC6A2 | |
| SCHEMBL2212930 | 0.85 | SMN1; SMN2 (0.60) | HIF1ASMN1; SMN2ARG1ARG2SLC6A2 | |
| SCHEMBL366770 | 0.82 | SMN1; SMN2 (0.62) | HIF1ASMN1; SMN2ARG1ARG2SLC6A2 | |
| SCHEMBL7924236 | 0.82 | SMN1; SMN2 (0.62) | HIF1ASMN1; SMN2ARG1ARG2SLC6A2 | |
| SCHEMBL22190022 | 0.82 | SMN1; SMN2 (0.62) | HIF1ASMN1; SMN2ARG1ARG2SLC6A2 | |
| SCHEMBL366771 | 0.82 | SMN1; SMN2 (0.62) | HIF1ASMN1; SMN2ARG1ARG2SLC6A2 | |
| SCHEMBL29278348 | 0.81 | ARG1 (0.60) | HIF1ASMN1; SMN2ARG1ARG2SLC6A2 | |
| SCHEMBL343695 | 0.81 | ARG1 (0.60) | HIF1ASMN1; SMN2ARG1ARG2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957205-B2 | Cycloalkane carboxamide derivatives and production process of same | SEIKAGAKU CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-8829209-B2 | Cycloalkylcarbonylamino acid ester derivative and process for producing the same | SEIKAGAKU CORPORATION (JP) | 2014-09-09 | — | — | US | disclosed |
| CN-101370773-B | Cycloalkanecarboxamide derivative and method for producing same | SEIKAGAKU KOGYO CO LTD | 2014-04-09 | — | — | CN | disclosed |
| EP-2036920-B1 | CYCLOALKYLCARBONYLAMINO ACID ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU KOGYO CO LTD (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20090156805-A1 | Cycloalkane Carboxamide Derivatives and Production Process of Same | SEIKAGAKU CORPORATION (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090137799-A1 | Cycloalkylcarbonylamino Acid Ester Derivative and Process for Producing The Same | SEIKAGAKU CORPORATION (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2036920-A1 | CYCLOALKYLCARBONYLAMINO ACID ESTER DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | SEIKAGAKU CORPORATION (JP) | 2009-03-18 | — | — | EP | disclosed |
| CN-101370773-A | Cycloalkanecarboxamide derivative and method for producing same | SEIKAGAKU KOGYO CO LTD (JP) | 2009-02-18 | — | — | CN | disclosed |
| EP-1972615-A1 | CYCLOALKANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME | SEIKAGAKU CORPORATION (JP) | 2008-09-24 | — | — | EP | disclosed |
| US-6818732-B2 | ABLE TO ELIMINATE CHAIN TRANSFER AND CHAIN TERMINATION SIDE REACTIONS FROM THESE POLYMERIZATIONS FOR NARROW MOLECULAR WEIGHT DISTRIBUTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-11-16 | — | — | US | disclosed |
| US-20030083460-A1 | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers | NATIONAL SCIENCE FOUNDATION | 2003-05-01 | — | — | US | disclosed |
| WO-2003020797-A1 | TRANSITION METAL INITIATORS FOR CONTROLLED POLY (BETA-PEPTIDE) SYNTHESIS FROM BETA-LACTAM MONOMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-03-13 | — | — | WO | disclosed |
| EP-0394311-A1 | RENIN INHIBITING PEPTIDES THAT CONTAIN AMINO AND HYDROXY DICARBOXYLIC ACIDS | THE UPJOHN COMPANY (US) | 1990-10-31 | — | — | EP | disclosed |
| WO-1989004833-A1 | RENIN INHIBITING PEPTIDES THAT CONTAIN AMINO AND HYDROXY DICARBOXYLIC ACIDS | THE UPJOHN COMPANY (US) | 1989-06-01 | — | — | WO | disclosed |
| US-4339589-A | Preparation of 4-substituted oxazolidin-5-ones | BASF AKTIENGESELLSCHAFT (DE) | 1982-07-13 | — | — | US | disclosed |
| US-4264771-A | Alkylation of substituted oxazolinone-(5) compounds | BASF AKTIENGESELLSCHAFT (DE) | 1981-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156805-A1 | Cycloalkane Carboxamide Derivatives and Production Process of Same | CTSK, CTSS, CTSB | HIF1A 2255/4885SMN1; SMN2 4556/4885ARG1 485/4885 |
| US-20090137799-A1 | Cycloalkylcarbonylamino Acid Ester Derivative and Process for Producing The Same | CTSK, CTSS, CTSE | HIF1A 3184/4885SMN1; SMN2 4555/4885ARG1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.